

Result Update || Current Market Price – Rs 1,300 || Target Price – Rs 1,420 || Upside – 9.2% || Date: 31st July 2026

Key Investment thesis

- Vinati Organics is entering a volume-led growth phase after a prolonged period of pricing-led earnings, with management maintaining confidence in achieving ~15% volume growth in FY27. Q1 FY27 revenue was primarily supported by a strong export performance, aided by rupee depreciation, while antioxidants witnessed healthy volume growth. Management expects a meaningful recovery in ATBS demand during H2 FY27, supported by improving industrial demand and a stronger second half, reaffirming the long-term growth outlook.
- Despite the healthy revenue performance, EBITDA margins remained under pressure as a sharp increase in raw material costs could only be passed on selectively across products, leading to margin compression. Nevertheless, management has reiterated its 26–27% EBITDA margin guidance, subject to raw material price movements and product mix. The key monitorables remain the recovery in ATBS volumes, successful commercialization of new specialty products, and the commissioning of the Veeral Organics facility, expected by December 2026 after re-engineering, which is unlikely to contribute materially to revenue before then.

Outlook

Vinati Organics is favourably placed to capitalize on the recovery, backed by its leadership in ATBS, expanding antioxidants portfolio, and healthy balance sheet. Management expects a stronger H2 FY27 with around **15% volume growth**, driven by recovering ATBS demand and improved capacity utilization.

However, margin expansion is likely to remain contingent on raw material cost normalization and product mix, while the successful commissioning of the Veeral Organics facility and commercialization of new specialty products will be key catalysts for sustaining long-term earnings growth.

Valuation

We expect the company to increase its Revenue/EBITDA/PAT at a CAGR of 13.7% / 8.2% / 7.0% for the period FY26-FY28. The company is currently trading at 26.5x FY28E and we value the company at a PE of 29x FY28E EPS, implying a target price of INR 1,420 with the upside of 9.2%. Rating: ACCUMULATE.

Key Risk


- Raw Material Price Volatility:** Sharp fluctuations in crude-linked raw material prices could compress margins if cost increases cannot be passed on to customers in a timely manner.
- Delay in ATBS Demand Recovery:** A slower-than-expected recovery in global industrial demand, particularly for ATBS, could impact volume growth and capacity utilization.
- Execution Risk in New Projects:** Delays in commissioning the Veeral Organics facility or slower commercialization of new specialty chemicals could postpone the next growth phase.

Particulars	
CMP	1,300
Market Cap (Cr)	13,482
Free Float Market Cap (Cr)	3,390
52 Week High / Low	1,878/1,203
Avg Daily Vol (1Yr.) shares	60,159
No. of Shares (Cr.)	10.4

Key Financials (Mn.)	FY26	FY27E	FY28E
Revenue	22,269	25,488	28,767
EBITDA	6,539	6,376	7,660
EBITDA (%)	29.4%	25.0%	26.6%
PAT	4,438	4,152	5,076
ROE	14.0%	11.9%	12.9%


Multiples	FY26	FY27E	FY28E
P/E (x)	30.37	32.46	26.55
EPS	42.8	40.0	49.0

Holding	Sep-25	Dec-25	March-26
Promoters	74.29	74.29	74.29
FII	3.77	3.72	3.72
DII	9.84	9.91	9.91
Public	12.11	12.10	12.10
TOTAL	100	100	100




Story in Charts


Volume-led topline surge of ~30% YoY masks limited pricing power amid RM inflation




Gross margin contracts as RM cost pass-through remains restricted to select products



Operating profit growth trails topline at ~7% YoY; input cost headwinds compress margins



Bottom-line growth muted at ~5% YoY; ATBS demand recovery key catalyst for H2 FY27



Source: Company Research, Deven Choksey Research

Result Snapshot

Particulars (INR Mn)	Q1 FY27	Q4 FY26	Q1 FY26	Q-o-Q	Y-o-Y
Revenue	6,959	6,039	5,420	15.2%	28.4%
Total Expenditure	5,254	4,336	3,823	21.2%	37.4%
Cost of Materials consumed	3,806	2,595	2,815	46.7%	35.2%
Purchase of Stock-in-trade	0	0	0	NA	NA
Changes in Inventories	-47	273	-232	(117.1%)	(79.9%)
Employee cost	505	433	424	16.6%	19.1%
Other Expenses	496	630	435	(21.3%)	14.0%
Power and fuel	494	406	382	21.7%	29.6%
EBITDA	1,705	1,703	1,597	0.1%	6.8%
EBITDA Margins (%)	24.5%	28.2%	29.5%	-370bps	-497bps
Depreciation & amortization	317	305	256	4.1%	24.1%
EBIT	1,388	1,398	1,341	(0.8%)	3.5%
Finance Cost	0	0	4	(100.0%)	(100.0%)
Other Income	90	204	74	(55.9%)	21.8%
PBT	1,478	1,602	1,412	(7.8%)	4.7%
Tax	389	363	370	7.0%	5.2%
PAT	1,089	1,239	1,042	(12.1%)	4.5%
PAT Margin	15.6%	20.5%	19.2%	-487bps	-358bps
Diluted EPS	10.5	11.9	10.0	(12.1%)	4.5%

Source: Company Research, Deven Choksey Research

Key Financials

Exhibit 1: Profit & Loss Statement

INR Mn	FY25	FY26	FY27E	FY28E
Revenue	22,482	22,269	25,488	28,767
COGS	11,960	10,274	13,448	14,552
Gross profit	10,522	11,995	12,040	14,214
Employee cost	1,396	1,754	1,894	2,158
Other expenses	1,804	2,026	1,885	2,244
Power & Fuel	1,513	1,676	1,884	2,153
EBITDA	5,809	6,539	6,376	7,660
EBITDA Margin	25.8%	29.4%	25.0%	26.6%
Depreciation & amortization	885	1,114	1,242	1,335
EBIT	4,924	5,425	5,134	6,326
Interest expense	5	4	0	0
Other income	443	527	450	480
PBT	5,362	5,948	5,584	6,806
Tax	1,309	1,510	1,432	1,729
Minority interest	0	0	0	0
PAT	4,053	4,438	4,152	5,076
Adj. PAT	4,053	4,438	4,152	5,076
EPS (INR)	39.1	42.8	40.0	49.0
Adj. EPS	39.1	42.8	40.0	49.0

Exhibit 2: Balance Sheet

INR Millions	FY25E	FY26	FY27E	FY28E
Equity				
Equity Capital	104	104	104	104
Other Equity	27,829	31,513	34,885	39,184
Non controlling interest	0	0	0	0
Total Equity	27,933	31,617	34,989	39,287
Non-Current Liabilities				
Deferred tax liabilities (Net)	1,519	1,838	1,838	1,838
Other Liability	207	186	110	124
Total Non-Current Liabilities	1,725	2,024	1,948	1,962
Current Liabilities				
Borrowings	626	0	0	0
Trade Payables	1,485	1,213	1,842	1,993
Other financial liabilities	197	258	223	252
Other current liabilities	826	784	1,483	1,674
Total Current Liabilities	3,133	2,254	3,548	3,919
Total Liabilities	32,791	35,895	40,485	45,168
Non-Current Assets				
Property Plants and Equipments	17,237	21,216	21,985	23,150
CWIP	4,382	2,141	2,141	2,141
Investments	259	0	0	0
Other current assets	536	373	977	1,102
Total Non-Current Assets	22,413	23,730	25,103	26,393
Current Assets				
Inventories	2,212	3,111	2,304	2,758
Trade Receivables	5,923	5,213	6,773	7,645
Cash and Bank	5	38	2,306	4,076
Bank Balance	34	23	23	23
Other current assets	2,204	3,781	3,984	4,281
Total Current Assets	10,378	12,166	15,391	18,783
Total Assets	32,791	35,895	40,494	45,176

Exhibit 3: Cash Flow Statement

INR Mn	FY25	FY26	FY27E	FY28E
Net Cash Generated From Operations	4,582	5,579	4,602	4,573
Net Cash Flow from/(used in) Investing Activities	(4,425)	(4,135)	(1,550)	(2,020)
Net Cash Flow from Financing Activities	(156)	(1,411)	(784)	(784)
Net Inc/Dec in cash equivalents	1	33	2,268	1,770
Opening Balance	4	5	38	2,306
Adjustments	0	0	0	0
Closing Balance Cash and Cash Equivalents	5	38	2,306	4,076

Source: Company Research, Deven Choksey Research

Vinati Organics Ltd.				Rating Legend (Expected over a 12-month period)	
Date	CMP (INR)	TP (INR)	Recommendation	Our Rating	Upside
31-July-26	1,300	1,420	ACCUMULATE	Buy	More than 15%
29-July-26	1,325	1,460	ACCUMULATE	Accumulate	5% – 15%
18-May-26	1,372	1,482	ACCUMULATE	Hold	0 – 5%
24-Nov-25	1,595	1,750	ACCUMULATE	Reduce	-5% – 0
25-Aug-25	1,675	1,880	ACCUMULATE	Sell	Less than – 5%
20-May-25	1,830	2,033	ACCUMULATE		

ANALYST CERTIFICATION:

ANALYST CERTIFICATION:

I, **Neel Mehta**, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

DRChoksey FinServ Private Limited (hereinafter referred to as DCFPL) is a registered member of SEBI as a Research Entity vide Registration No. INH000011246 under SEBI (Research Analyst) Regulations, 2014, Portfolio Managers Entity vide Registration No. INP000007906 under SEBI (PORTFOLIO MANAGERS) Regulations, 2020 & Investment Adviser Entity vide Registration No. INA000017903 under SEBI (INVESTMENT ADVISERS) REGULATIONS, 2013.

The information and opinions in this report have been prepared by DCFPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of DCFPL. While I would endeavor to update the information herein on a reasonable basis, DCFPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent DCFPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily, and such suspension is in compliance with applicable regulations and/or DCFPL policies, in circumstances where DCFPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. DCFPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. DCFPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

I submit that no material disciplinary action has been taken on DCFPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

DCFPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, I, **Neel Mehta** Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

DCFPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company.

DCFPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. DCFPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither DCFPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that **Neel Mehta**, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

DCFPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

The securities quoted are for illustration only and are not recommendatory.

DCFPL (Research Entity) and its research analysts uses Artificial Intelligence tools.

DCFPL and or its Research analysts shall be solely responsible for the security, confidentiality and integrity of the client data, use of any other information or data for research services, research services based on output of Artificial Intelligence tools and compliance with any law for the time being in force.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restrictions.

Investment in securities are subject to market risks, read all the documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

- Please send your feedback to research.retail@devenchoksey.com

DRChoksey FinServ Private Limited

CIN Number -U67100MH2020PTC352816

Registered Office and Corporate Office:

5th Floor Abhishek Building, Behind Monginis Cake Factory, Off New Link Road, Andheri West, Mumbai-400058